AN2 Therapeutics, Inc. (“AN2 Therapeutics” or the “Company”) is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The Company’s initial product candidate is epetraborole, a once-daily, oral treatment for patients with non-tuberculous mycobacterial, or NTM, lung disease, a rare, chronic and progressive infectious disease caused by bacteria known as mycobacteria that leads to irreversible lung damage and can be fatal. Epetraborole has broad spectrum antimycobacterial activity through inhibition of an essential and universal step in bacterial protein synthesis.